Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Werte in diesem Artikel
DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business update on Tuesday, January 14, 2025, at 9:45 a.m. PST / 5:45 p.m. GMT.
A live audio webcast of the presentation may be accessed via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be available on the website for 30 days following the conference.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Contacts:
Investors:
Jeff Macdonald
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland, +353 1 634 3211
U.S., +1 650 496 2717
Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland, +353 1 637 2141
U.S., +1 215 867 4948
Logo - https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_New_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302334239.html
Ausgewählte Hebelprodukte auf Jazz Pharmaceuticals
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Jazz Pharmaceuticals
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Jazz Pharmaceuticals PLC
Analysen zu Jazz Pharmaceuticals PLC
Datum | Rating | Analyst | |
---|---|---|---|
11.06.2019 | Jazz Pharmaceuticals Overweight | Barclays Capital | |
14.12.2018 | Jazz Pharmaceuticals Peer Perform | Wolfe Research | |
08.11.2018 | Jazz Pharmaceuticals Buy | B. Riley FBR | |
08.08.2018 | Jazz Pharmaceuticals Buy | Stifel, Nicolaus & Co., Inc. | |
23.03.2018 | Jazz Pharmaceuticals Neutral | H.C. Wainwright & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
11.06.2019 | Jazz Pharmaceuticals Overweight | Barclays Capital | |
08.11.2018 | Jazz Pharmaceuticals Buy | B. Riley FBR | |
08.08.2018 | Jazz Pharmaceuticals Buy | Stifel, Nicolaus & Co., Inc. | |
08.11.2017 | Jazz Pharmaceuticals Outperform | RBC Capital Markets | |
19.10.2017 | Jazz Pharmaceuticals Buy | FBR & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2018 | Jazz Pharmaceuticals Peer Perform | Wolfe Research | |
23.03.2018 | Jazz Pharmaceuticals Neutral | H.C. Wainwright & Co. | |
05.12.2017 | Jazz Pharmaceuticals Neutral | Mizuho | |
10.11.2017 | Jazz Pharmaceuticals Neutral | H.C. Wainwright & Co. | |
25.08.2017 | Jazz Pharmaceuticals Neutral | H.C. Wainwright & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Jazz Pharmaceuticals PLC nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen